MX2022014133A - Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6. - Google Patents
Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6.Info
- Publication number
- MX2022014133A MX2022014133A MX2022014133A MX2022014133A MX2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A MX 2022014133 A MX2022014133 A MX 2022014133A
- Authority
- MX
- Mexico
- Prior art keywords
- breast cancer
- gdc
- cdk4
- inhibitor
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023501P | 2020-05-12 | 2020-05-12 | |
| PCT/US2021/031491 WO2021231250A1 (en) | 2020-05-12 | 2021-05-10 | Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014133A true MX2022014133A (es) | 2022-11-30 |
Family
ID=76250442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014133A MX2022014133A (es) | 2020-05-12 | 2021-05-10 | Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11918561B2 (https=) |
| EP (1) | EP4149476A1 (https=) |
| JP (3) | JP2023500558A (https=) |
| KR (1) | KR20230009390A (https=) |
| CN (2) | CN115551513B (https=) |
| AU (1) | AU2021272100B2 (https=) |
| CA (1) | CA3182018A1 (https=) |
| IL (1) | IL298071A (https=) |
| MX (1) | MX2022014133A (https=) |
| TW (1) | TWI800827B (https=) |
| WO (1) | WO2021231250A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023009374A (es) * | 2021-02-16 | 2023-08-16 | Genentech Inc | Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib. |
| IL315153A (en) * | 2022-03-14 | 2024-10-01 | Genentech Inc | Combined treatments for breast cancer |
| CN121337802B (zh) * | 2025-10-23 | 2026-04-14 | 安徽益普克医药科技发展有限公司 | 一种雌激素降解剂衍生物及其制备方法与用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102529049B1 (ko) * | 2013-08-14 | 2023-05-08 | 노파르티스 아게 | 암의 치료를 위한 조합 요법 |
| KR102358935B1 (ko) * | 2014-02-12 | 2022-02-04 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 전자 기기 |
| KR102785474B1 (ko) * | 2014-12-18 | 2025-03-26 | 에프. 호프만-라 로슈 아게 | 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도 |
| JP7019422B2 (ja) * | 2015-04-29 | 2022-02-15 | ラジウス ファーマシューティカルズ，インコーポレイテッド | 癌を治療するための方法 |
| KR20180119570A (ko) | 2016-03-15 | 2018-11-02 | 메리맥 파마슈티컬즈, 인크. | 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료 |
| LT3810283T (lt) * | 2018-06-21 | 2023-08-25 | F. Hoffmann-La Roche Ag | 3-((1r,3r)-1-(2,6-difluor-4-((1-(3-fluorpropil)azetidin-3- il)amino) fenil)-3-metil-1,3,4,9-tetrahidro-2h-pirido[3,4-b]indol-2-il)- 2,2- difluorpropan-1-olio tartrato druskos kietosios formos, jų paruošimo procesas ir jų naudojimo būdai vėžiui gydyti |
| CA3109090A1 (en) | 2018-08-17 | 2020-02-20 | F. Hoffmann-La Roche Ag | Diagnostic and therapeutic methods for the treatment of breast cancer |
| JP7826068B2 (ja) * | 2022-03-11 | 2026-03-09 | 本田技研工業株式会社 | パワーユニット、及びパワーユニットを搭載した作業機 |
-
2021
- 2021-05-10 TW TW110116831A patent/TWI800827B/zh active
- 2021-05-10 MX MX2022014133A patent/MX2022014133A/es unknown
- 2021-05-10 JP JP2022515505A patent/JP2023500558A/ja not_active Withdrawn
- 2021-05-10 CN CN202180034978.8A patent/CN115551513B/zh active Active
- 2021-05-10 KR KR1020227039518A patent/KR20230009390A/ko active Pending
- 2021-05-10 IL IL298071A patent/IL298071A/en unknown
- 2021-05-10 EP EP21729702.7A patent/EP4149476A1/en active Pending
- 2021-05-10 WO PCT/US2021/031491 patent/WO2021231250A1/en not_active Ceased
- 2021-05-10 CN CN202510482379.2A patent/CN120324434A/zh active Pending
- 2021-05-10 US US17/316,455 patent/US11918561B2/en active Active
- 2021-05-10 AU AU2021272100A patent/AU2021272100B2/en active Active
- 2021-05-10 CA CA3182018A patent/CA3182018A1/en active Pending
-
2023
- 2023-08-16 JP JP2023132463A patent/JP2023175688A/ja active Pending
-
2024
- 2024-01-26 US US18/423,596 patent/US12303495B2/en active Active
- 2024-03-21 JP JP2024045217A patent/JP2024102045A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021231250A1 (en) | 2021-11-18 |
| US20240173306A1 (en) | 2024-05-30 |
| CN115551513B (zh) | 2025-05-02 |
| CN115551513A (zh) | 2022-12-30 |
| JP2024102045A (ja) | 2024-07-30 |
| TWI800827B (zh) | 2023-05-01 |
| AU2024202832A1 (en) | 2024-05-23 |
| IL298071A (en) | 2023-01-01 |
| JP2023175688A (ja) | 2023-12-12 |
| CA3182018A1 (en) | 2021-11-18 |
| TW202203913A (zh) | 2022-02-01 |
| US11918561B2 (en) | 2024-03-05 |
| EP4149476A1 (en) | 2023-03-22 |
| AU2021272100A1 (en) | 2022-11-17 |
| CN120324434A (zh) | 2025-07-18 |
| KR20230009390A (ko) | 2023-01-17 |
| AU2021272100B2 (en) | 2024-09-12 |
| US12303495B2 (en) | 2025-05-20 |
| US20210353601A1 (en) | 2021-11-18 |
| JP2023500558A (ja) | 2023-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2025002208A1 (es) | Inhibidores de kif18a para el tratamiento de enfermedades neoplásicas | |
| MX2022014133A (es) | Tratamiento para cancer de mama usando tratamientos conjuntos que comprenden gdc-9545 y un inhibidor de cdk4/6. | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CR11486A (es) | Tratamiento de cancer uterino y cancer de ovario con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
| DOP2010000141A (es) | Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales | |
| MX2019011221A (es) | Terapia de combinacion para el tratamiento o prevencion de tumores. | |
| MX381582B (es) | Terapia de combinacion para el tratamiento de neoplasias malignas. | |
| MX2018004587A (es) | Terapia de combinacion para tratar tumores malignos. | |
| MX386735B (es) | Terapia de combinacion para tratar tumores malignos. | |
| MX2018006674A (es) | Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control. | |
| MX2022006701A (es) | Terapia combinada para el tratamiento de neoplasias malignas. | |
| BR112022008295A2 (pt) | Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer | |
| CL2021001623A1 (es) | Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer | |
| BR112023005160A2 (pt) | Terapia de combinação para o tratamento de câncer | |
| BR112019019261A2 (pt) | Terapias de combinação para o tratamento de câncer de mama | |
| MX2024006678A (es) | Inhibidor de cdk4 para el tratamiento del cancer. | |
| CL2025001869A1 (es) | Uso de diferentes compuestos inhibidores de quinasas para tratar cáncer. | |
| MX2021015403A (es) | Terapia de combinacion que comprende un conjugado de anticuerpo-farmaco anti-cd19 y un inhibidor de pi3k o un agente secundario. | |
| ZA202406390B (en) | Compounds and their use in treating cancer | |
| MX2021009182A (es) | Antiandrogenos para el tratamiento de cancer de prostata metastasico sensible a la castracion. | |
| CL2023003090A1 (es) | Combinaciones de composiciones terapéuticas y usos para tratar cánceres | |
| AR116024A1 (es) | Métodos de tratamiento de enfermedades neurodegenerativas | |
| MX2021003160A (es) | Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama. | |
| MX2024012368A (es) | Terapia combinada para el tratamiento del cancer | |
| MX2023009374A (es) | Tratamiento de cancer de mama mediante el uso de tratamientos conjuntos que comprenden gdc-9545 y abemaciclib o ribociclib. |